

Prostate cancer: diagnosis and management (update)

Review search strategies

NICE guideline <number>

Review search strategies

October 2018

*Commissioned by the National Institute
for Health and Care Excellence*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE [2018]. All rights reserved. Subject to [Notice of rights](#).

Contents

| | | |
|----------|--|-----------|
| 1 | Scoping search strategies | 5 |
| 1.1 | Scoping searches..... | 5 |
| 1.2 | Main searches..... | 6 |
| 1.3 | Identification of evidence for review questions..... | 6 |
| 2 | Review question search strategies | 7 |
| 2.1 | Search strategy review questions 1 and 3 | 7 |
| 2.2 | Search strategy review question 2..... | 8 |
| 2.3 | Search strategy review question 4..... | 9 |
| 2.4 | Search strategy review question 5 and 6..... | 9 |
| 2.5 | Search strategy review questions 7 | 10 |
| 2.6 | Search strategy review question 8..... | 11 |
| 2.7 | Search strategy review questions 9..... | 11 |
| 3 | Study Design Filters | 14 |
| 4 | Health economics search strategy | 17 |
| 4.1 | Economic evaluations and quality of life data | 17 |

1 Scoping search strategies

1.1 Scoping searches

Scoping searches were undertaken on the following websites and databases (listed in alphabetical order) in March 2017 to provide information for scope development and project planning. Browsing or simple search strategies were employed.

| Guidelines/website | Systematic review/economic evaluations |
|--|--|
| Audit Commission (archived) | Campbell Collaboration |
| Canadian Medical Association Infobase | Cochrane Database of Systematic Reviews (CDSR) |
| Care Quality Commission | Database of Abstracts of Reviews of Effects (DARE) – last updated Dec 2014 |
| Core Outcome Measures in Effectiveness Trials (COMET) | Evidence Uncertainties (DUETS) |
| Department of Health | Health Technology Assessment (HTA) Database |
| General Medical Council | International Guideline Library |
| Guidelines & Audit Implementation Network (GAIN) | NHS Economic Evaluation Database (NHS EED) – last updated December 2014 |
| Guidelines International Network (GIN) | National Institute for Health Research (NIHR) Health Technology Assessment Programme |
| Health and Social Care Information Centre | NIHR Health Services and Delivery Research (HS&DR) |
| Healthtalk Online | PROSPERO |
| Medicines and Products Regulatory Agency (MHRA) | TRIP Database |
| National Audit Office | |
| National Clinical Audit and Patient Outcomes Programme | |
| National Health and Medical Research Council - Australia | |
| National Institute for Health and Care Excellence (NICE) - published & in development guidelines | |
| National Institute for Health and Care Excellence (NICE) - Topic Selection | |
| National Prescribing Centre (legacy site) | |
| NHS Choices | |
| NHS England | |
| NICE Clinical Knowledge Summaries (CKS) | |
| NICE Evidence Search | |
| NICE Shared Learning Database | |
| Patient UK | |
| Patient Voices | |
| Public Health England | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal College of Psychiatrists | |
| Royal College of Radiologists | |
| Royal College of Surgeons | |
| Scottish Government | |

| Guidelines/website | Systematic review/economic evaluations |
|---|--|
| Scottish Intercollegiate Guidelines Network (SIGN) UK Data Service US National Guideline Clearinghouse UK National Statistics YouthHealth Talk Cancer Stats British Association of Urological Surgeons British Uro-Oncology Group BUPA Foundation Clatterbridge Centre for Oncology Macmillan Cancer Support National Cancer Intelligence Network National Cancer Research Institute Prostate Cancer UK Prostate Cancer Support Association (North of England) Prostate Cancer Support Association (Central England) Orchid – Fighting male cancer Tackle Prostate Cancer The Christie NHS Foundation Trust The Royal Marsden NHS Foundation Trust | |

1.2 Main searches

Bibliographic databases searched for the guideline

- Cochrane Database of Systematic Reviews – CDSR (Wiley)
- Cochrane Central Register of Controlled Trials – CENTRAL (Wiley)
- Database of Abstracts of Reviews of Effects – DARE (Wiley)
- Health Technology Assessment Database – HTA (Wiley)
- EMBASE (Ovid)
- MEDLINE (Ovid)
- MEDLINE Epub Ahead of Print (Ovid)
- MEDLINE In-Process (Ovid)

1.3 Identification of evidence for review questions

The searches were conducted between October 2017 and May 2018 for 9 review questions (RQ).

Searches were re-run in July 2018.

Where appropriate, study design filters (either designed in-house (NICE) or by McMaster or the Scottish Intercollegiate Guidelines Network (SIGN)) were used to limit the retrieval to, for example, randomised controlled trials. Details of the study design filters used can be found in section D3.

2 Review question search strategies

2.1 Search strategy review questions 1 and 3

RQ1: Which of the following, alone or in combination, constitutes the most clinical and cost-effective pathway for diagnosing prostate cancer:

- Multiparametric or biparametric MRI alone
- MRI influenced TRUS biopsy
- TRUS biopsy alone

RQ3: Which of the following, alone or in combination, constitutes the most clinical and cost-effective pathway for excluding the clinically significant progression of prostate cancer in people with low to intermediate risk (as defined in NICE CG175): Multiparametric/ functional MRI, TRUS biopsy, Transperineal template biopsy?

Table 1: search strategy RQ1 and 3

| Medline strategy, searched 23rd January 2018 | |
|--|--|
| Database: Ovid MEDLINE(R) 1946 to Present with Daily Update | |
| 1 | exp Prostatic Neoplasms/ |
| 2 | Prostatic Intraepithelial Neoplasia/ |
| 3 | (prostat* adj4 (neoplas* or cancer* or carcinoma* or adenocarcinom* or tumour* or tumor* or malignan* or metasta* or angiosarcoma* or sarcoma* or teratoma* or lymphoma* or blastoma* or microcytic* or carcino* or leiomyosarcoma* or lump*)).tw. |
| 4 | PIN.tw. |
| 5 | or/1-4 |
| 6 | *Magnetic Resonance Imaging/ |
| 7 | (magnet* adj2 (resonance* or imag* or scan* or spectroscop*)).tw. |
| 8 | (MR adj2 (resonance* or imag* or scan* or spectroscop*)).tw. |
| 9 | (Dynamic contrast* enhanc* adj2 (MR* or magnet*)).tw. |
| 10 | (contrast* adj2 (imag* or scan*)).tw. |
| 11 | ((MRI or MRSI or MP-MR* or MPMR*) adj4 prostat*).tw. |
| 12 | turbo spin echo*.tw. |
| 13 | ((diffusion* or weight*) adj2 imag*).tw. |
| 14 | ((DWI or DCE-MRI or T2W or TSE or T2-weighted MRI*) adj4 prostat*).tw. |
| 15 | (Multi-parametric or multiparametric* or biparametric* or bi-parametric*).tw. |
| 16 | *biopsy/ or *image-guided biopsy/ |
| 17 | ((transrectal* or trans-rectal* or transperineal* or trans-perineal*) adj2 (ultrasound* or biops*)).tw. |
| 18 | ((saturat* or extend* or templat*) adj2 (ultrasound* or biops*)).tw. |
| 19 | ((TRUS or TRUSB) adj4 prostat*).tw. |
| 20 | or/6-19 |
| 21 | 5 and 20 |
| 22 | Animals/ not Humans/ |
| 23 | 21 not 22 |
| 24 | Comment/ or Letter/ or Editorial/ or Historical article/ or (conference abstract or conference paper or "conference review" or letter or editorial or case report).pt. |
| 25 | 23 not 24 |
| 26 | limit 25 to english language |

Note: McMaster diagnosis filter plus prostate diagnosis subhedings (OVID) were appended to the strategy. Date limit applied from 2007 to 2018

Search also run with the NICE systematic review and RCT study filters on 10th April 2018. Date limit applied from 2007 to 2018.

2.2 Search strategy review question 2

RQ2: What is the clinical and cost-effectiveness of active surveillance, radical prostatectomy or radical radiotherapy compared to each other for people with localised prostate cancer?

Table 2: search strategy RQ2

| Medline strategy, searched 14 th March 2018 | |
|---|--|
| Database: Ovid MEDLINE(R) 1946 to Present with Daily Update | |
| 1 | exp Prostatic Neoplasms/ |
| 2 | Prostatic Intraepithelial Neoplasia/ |
| 3 | (prostat* adj4 (neoplas* or cancer* or carcinoma* or adenocarcinom* or tumour* or tumor* or malignan* or metasta* or angiosarcoma* or sarcoma* or teratoma* or lymphoma* or blastoma* or microcytic* or carcino* or leiomyosarcoma* or lump*)).tw. |
| 4 | PIN.tw. |
| 5 | or/1-4 |
| 6 | Watchful Waiting/ |
| 7 | ((active* or watch* or expect* or conservat*) adj (surveillan* or monitor* or observat* or wait* or manag*)).tw. |
| 8 | ((deferr* or delay*) adj1 (treat* or therap*)).tw. |
| 9 | or/6-8 |
| 10 | exp Prostatic Neoplasms/su |
| 11 | exp Prostatectomy/ |
| 12 | (radical adj4 prostatectom*).tw. |
| 13 | or/10-12 |
| 14 | exp radiotherapy/ |
| 15 | radiotherap*.tw. |
| 16 | (radiat* adj4 (therap* or treatment*)).tw. |
| 17 | ((external* or conformal*) adj4 (irradiat* or therap* or treat*)).tw. |
| 18 | ((interstitial* or intracavit* or implant* or surface* or internal*) adj4 (irradiat* or radiation*)).tw. |
| 19 | curietherap*.tw. |
| 20 | (radioisotope* adj4 (irradiat* or therap* or treat*)).tw. |
| 21 | ((seed* or permanent*) adj2 implant*).tw. |
| 22 | or/14-21 |
| 23 | Brachytherapy/ |
| 24 | brachytherap*.tw. |
| 25 | exp radiotherapy dosage/ |
| 26 | exp dose-response relationship, radiation/ |
| 27 | (Hyperfraction* or Hyper-fraction* or Hyper fraction* or Hypofraction* or Hypo-fraction* or Hypo fraction*).tw. |
| 28 | ((optim* or fraction* or respons*) adj4 (dose* or dosage or schedule*)).tw. |
| 29 | ((high* or full* or maximum* or larg* or escalat* or supplement* or low* or minimum* or small*) adj4 (dose* or dosage* or schedule*)).tw. |
| 30 | (HDR or LDR).tw. |
| 31 | or/23-30 |
| 32 | 22 and 31 |
| 33 | 9 or 13 or 22 or 32 |
| 34 | 5 and 33 |
| 35 | Animals/ not Humans/ |
| 36 | 34 not 35 |
| 37 | Comment/ or Letter/ or Editorial/ or Historical article/ or (conference abstract or conference paper or "conference review" or letter or editorial or case report).pt. |
| 38 | 36 not 37 |
| 39 | limit 38 to english language |

Medline strategy, searched 14th March 2018

Database: Ovid MEDLINE(R) 1946 to Present with Daily Update

Note: SIGN systematic review and RCT study filters appended to strategy. Date limit applied from 2007 to 2018.

2.3 Search strategy review question 4

RQ4: What is the optimal dose and fractionation schedule for people with localised prostate cancer (T1b–T3a N0 M0) who are treated with radical radiotherapy?

Table 3: search strategy RQ4

Medline strategy, searched 18th December 2017

Database: Ovid MEDLINE(R) 1946 to Present with Daily Update

- 1 exp Prostatic Neoplasms/
- 2 Prostatic Intraepithelial Neoplasia/
- 3 (prostat* adj4 (neoplas* or cancer* or carcinoma* or adenocarcinom* or tumour* or tumor* or malignan* or metasta* or angiosarcoma* or sarcoma* or teratoma* or lymphoma* or blastoma* or microcytic* or carcino* or leiomyosarcoma* or lump*)).tw.
- 4 PIN.tw.
- 5 or/1-4
- 6 exp radiotherapy/
- 7 radiotherap*.tw.
- 8 (radiat* adj4 (therap* or treatment*)).tw.
- 9 ((external* or conformal*) adj4 (irradiat* or therap* or treat*)).tw.
- 10 ((interstitial* or intracavit* or implant* or surface* or internal*) adj4 (irradiat* or radiation*)).tw.
- 11 curietherap*.tw.
- 12 (radioisotope* adj4 (irradiat* or therap* or treat*)).tw.
- 13 ((seed* or permanent*) adj2 implant*).tw.
- 14 or/6-13
- 15 Brachytherapy/
- 16 brachytherap*.tw.
- 17 exp radiotherapy dosage/
- 18 exp dose-response relationship, radiation/
- 19 (Hyperfraction* or Hyper-fraction* or Hyper fraction* or Hypofraction* or Hypo-fraction* or Hypo fraction*).tw.
- 20 ((optim* or fraction* or respons* or relation* or dependence* or effect* or scheme* or curve*) adj4 (dose* or dosage or schedule*)).tw.
- 21 ((high* or full* or maximum* or larg* or escalat* or supplement* or low* or minimum* or small*) adj4 (dose* or dosage* or schedule*)).tw.
- 22 (HDR or LDR).tw.
- 23 or/15-22
- 24 5 and 14 and 23
- 25 Animals/ not Humans/
- 26 24 not 25
- 27 Comment/ or Letter/ or Editorial/ or Historical article/ or (conference abstract or conference paper or "conference review" or letter or editorial or case report).pt.
- 28 26 not 27
- 29 limit 28 to english language

Note: NICE systematic review and RCT study filters appended to strategy. Date limit applied from 2008 to 2017.

2.4 Search strategy review question 5 and 6

RQ5: What is the most clinically and cost-effective scheduling of docetaxel added to standard treatment for the treatment of hormone-sensitive locally-advanced prostate cancer?

RQ6: What is the most clinically and cost-effective scheduling of docetaxel added to standard treatment for the treatment of hormone-sensitive metastatic prostate cancer?

Table 4: search strategy RQ5 and 6

| Medline strategy, searched 24 th October 2017 | |
|--|--|
| Database: Ovid MEDLINE(R) 1946 to October Week 2 2017 | |
| 1 | exp Prostatic Neoplasms/ |
| 2 | Prostatic Intraepithelial Neoplasia/ |
| 3 | (prostat* adj4 (neoplas* or cancer* or carcinoma* or adenocarcinom* or tumour* or tumor* or malignan* or metasta* or angiosarcoma* or sarcoma* or teratoma* or lymphoma* or blastoma* or microcytic* or carcino* or leiomyosarcoma* or lump*)).tw. |
| 4 | PIN.tw. |
| 5 | or/1-4 |
| 6 | Taxoids/ |
| 7 | (Docetaxel* or Daxotel* or Docefrez* or Taxceus* or Taxoter* or Taxespira* or Textot*).tw. |
| 8 | or/6-7 |
| 9 | 5 and 8 |
| 10 | Animals/ not Humans/ |
| 11 | 9 not 10 |
| 12 | Comment/ or Letter/ or Editorial/ or Historical article/ or (conference abstract or conference paper or "conference review" or letter or editorial or case report).pt. |
| 13 | 11 not 12 |
| 14 | limit 13 to english language |

Note: NICE systematic review and RCT study filters appended to strategy.

2.5 Search strategy review questions 7

RQ7: What is the clinical and cost-effectiveness of the use of bisphosphonates in people with hormone- relapsed metastatic prostate cancer?

Table 5: search strategy RQ7

| Medline strategy, searched 10 th October 2017 | |
|--|--|
| Database: Ovid MEDLINE(R) 1946 to September Week 4 2017 | |
| 1 | exp Prostatic Neoplasms/ |
| 2 | Prostatic Intraepithelial Neoplasia/ |
| 3 | (prostat* adj4 (neoplas* or cancer* or carcinoma* or adenocarcinom* or tumour* or tumor* or malignan* or metasta* or angiosarcoma* or sarcoma* or teratoma* or lymphoma* or blastoma* or microcytic* or carcino* or leiomyosarcoma* or lump*)).tw. |
| 4 | PIN.tw. |
| 5 | or/1-4 |
| 6 | Diphosphonates/ |
| 7 | (Bisphospon* or diphospon*).tw. |
| 8 | (Zoledron* or zolindia or zometa or aclasta).tw. |
| 9 | (Ibandron* or bonviva or bondron* or iasibon or quodixor).tw. |
| 10 | Pamidron*.tw. |
| 11 | Clodronic Acid/ |
| 12 | (Clodron* or Ioron or bonefos or clasteon or aredia).tw. |
| 13 | Alendronate/ |
| 14 | (Alendron* or binosto or fosamax or fosavance).tw. |
| 15 | Risedronate Sodium/ |
| 16 | (Risedron* or actonel).tw. |
| 17 | or/6-16 |
| 18 | 5 and 17 |
| 19 | Animals/ not Humans/ |
| 20 | 18 not 19 |
| 21 | Comment/ or Letter/ or Editorial/ or Historical article/ or (conference abstract or conference paper or "conference review" or letter or editorial or case report).pt. |

Medline strategy, searched 10th October 2017

Database: Ovid MEDLINE(R) 1946 to September Week 4 2017

- 22 20 not 21
- 23 limit 22 to english language

Note: NICE systematic review and RCT study filters appended to strategy.

2.6 Search strategy review question 8

RQ8: What is the most clinically and cost-effective follow-up protocol for people who have a raised PSA, negative MRI and/ or negative biopsy?

Table 6: search strategy RQ8

Medline strategy, searched 24th April 2018

Database: Ovid MEDLINE(R) 1946 to present with daily update

- 1 Prostate-Specific Antigen/
- 2 (Prostate* specific antigen adj2 (rais* or high* or elevate* or rise* or increase*)).tw.
- 3 (PSA adj2 (rais* or high* or elevate* or rise* or increase*)).tw.
- 4 (Kallikrein or semenogelase or seminin or gamma seminoprotein or gamma-seminoprotein or HK3).tw.
- 5 Prostate Health Index.tw.
- 6 PHI.tw.
- 7 or/1-6
- 8 *Magnetic Resonance Imaging/
- 9 (magnet* adj2 (resonance* or imag* or scan* or spectroscop*)).tw.
- 10 (MR adj2 (resonance* or imag* or scan* or spectroscop*)).tw.
- 11 (Dynamic contrast* enhanc* adj2 (MR* or magnet*)).tw.
- 12 (contrast* adj2 (imag* or scan*)).tw.
- 13 ((MRI or MRSI or MP-MR* or MPMR*) adj4 prostat*).tw.
- 14 turbo spin echo*.tw.
- 15 ((diffusion* or weight*) adj2 imag*).tw.
- 16 ((DWI or DCE-MRI or T2W or TSE or T2-weighted MRI*) adj4 prostat*).tw.
- 17 (Multi-parametric or multiparametric* or biparametric* or bi-parametric*).tw.
- 18 or/8-17
- 19 *biopsy/ or *image-guided biopsy/
- 20 ((transrectal* or trans-rectal* or transperineal* or trans-perineal*) adj2 (ultrasound* or biops*)).tw.
- 21 ((saturat* or extend* or templat* or negative*) adj2 (ultrasound* or biops*)).tw.
- 22 ((TRUS or TRUSB) adj4 prostat*).tw.
- 23 or/19-22
- 24 7 and 18
- 25 7 and 23
- 26 or/24-25
- 27 Animals/ not Humans/
- 28 26 not 27
- 29 Comment/ or Letter/ or Editorial/ or Historical article/ or (conference abstract or conference paper or "conference review" or letter or editorial or case report).pt.
- 30 28 not 29
- 31 limit 30 to english language

Note: McMaster diagnosis filter plus prostate diagnosis subhedings (OVID) appended to the strategy.

2.7 Search strategy review questions 9

RQ9: What is the most clinically and cost-effective follow-up protocol for people with prostate cancer who have had radical treatment, with specific regard to: duration of follow-up, frequency of follow-up appointments, the type of examination or blood tests, the respective roles of primary and secondary care in follow-up?

Table 7: search strategy RQ9

| Medline strategy, searched 30 th May 2018 | |
|---|---|
| Database: Ovid MEDLINE(R) 1946 to Present with Daily Update | |
| 1 | exp Prostatic Neoplasms/ |
| 2 | Prostatic Intraepithelial Neoplasia/ |
| 3 | (prostat* adj4 (neoplas* or cancer* or carcinoma* or adenocarcinom* or tumour* or tumor* or malignan* or metasta* or angiosarcoma* or sarcoma* or teratoma* or lymphoma* or blastoma* or microcytic* or carcino* or leiomyosarcoma* or lump*)).tw. |
| 4 | PIN.tw. |
| 5 | or/1-4 |
| 6 | exp Prostatic Neoplasms/su |
| 7 | exp Prostatectomy/ |
| 8 | (radical adj4 prostatectom*).tw. |
| 9 | (radical adj4 (therap* or treatment*)).tw. |
| 10 | or/6-9 |
| 11 | exp radiotherapy/ |
| 12 | radiotherap*.tw. |
| 13 | (radiat* adj4 (therap* or treatment*)).tw. |
| 14 | ((external* or conformal*) adj4 (irradiat* or therap* or treat*)).tw. |
| 15 | ((interstitial* or intracavit* or implant* or surface* or internal*) adj4 (irradiat* or radiation*)).tw. |
| 16 | curietherap*.tw. |
| 17 | (radioisotope* adj4 (irradiat* or therap* or treat*)).tw. |
| 18 | ((seed* or permanent*) adj2 implant*).tw. |
| 19 | Brachytherapy/ |
| 20 | brachytherap*.tw. |
| 21 | (Hyperfraction* or Hyper-fraction* or Hyper fraction* or Hypofraction* or Hypo-fraction* or Hypo fraction*).tw. |
| 22 | ((high* or full* or maximum* or larg* or escalat* or supplement* or low* or minimum* or small*) adj4 (dose* or dosage* or schedule*)).tw. |
| 23 | (HDR or LDR).tw. |
| 24 | or/11-23 |
| 25 | 10 or 24 |
| 26 | Follow-Up Studies/ or Aftercare/ |
| 27 | ((Aftercare or after car* or after-car* or after treat or after-treat*) adj6 prostat*).tw. |
| 28 | ((Follow-up* or follow up*) adj6 prostat*).tw. |
| 29 | ("follow-up protocol*" or "follow-up strateg*" or "follow-up appointment*" or "follow-up clinic*" or "follow-up car*" or "follow-up review*" or "follow-up regime*" or "follow-up checklist*" or "follow-up procedure*" or "follow-up treat*" or "follow-up therap*" or "follow-up program*" or "follow-up plan*" or "follow-up polic*" or "follow-up approach*" or "follow-up schedule*" or "follow-up scheme*" or "follow-up practice*" or "follow-up system*").tw. |
| 30 | ("follow up protocol*" or "follow up strateg*" or "follow up appointment*" or "follow up clinic*" or "follow up car*" or "follow up review*" or "follow up regime*" or "follow up checklist*" or "follow up procedure*" or "follow up treat*" or "follow up therap*" or "follow up program*" or "follow up plan*" or "follow up polic*" or "follow up approach*" or "follow up schedule*" or "follow up scheme*" or "follow up practice*" or "follow up system*").tw. |
| 31 | ("repeat* protocol*" or "repeat* strateg*" or "repeat* appointment*" or "repeat* clinic*" or "repeat* car*" or "repeat* review*" or "repeat* regime*" or "repeat* checklist*" or "repeat* procedure*" or "repeat* treat*" or "repeat* program*" or "repeat* plan*" or "repeat* polic*" or "repeat* schedule*" or "repeat* scheme*" or "repeat* system*").tw. |
| 32 | ("review* protocol*" or "review* strateg*" or "review* appointment*" or "review* clinic*" or "review* car*" or "review* checklist*" or "review* procedure*" or "review* treat*" or "review* program*" or "review* plan*" or "review* polic*" or "review* approach*" or "review* schedule*" or "review* scheme*" or "review* system*").tw. |
| 33 | *Neoplasm Recurrence, Local/ |
| 34 | Recurrence/ and exp Prostatic Neoplasms/ |
| 35 | Disease-Free Survival/ and exp Prostatic Neoplasms/ |
| 36 | Survivorship/ and exp Prostatic Neoplasms/ |
| 37 | ((Overall or free) adj1 surviv*).tw. |
| 38 | Survivorship*.tw. |
| 39 | ((Disease* or pathological*) adj1 (progress* or surviv* or recurrence*)).tw. |
| 40 | (Clinical adj1 (progress* or recurrence*)).tw. |

Medline strategy, searched 30th May 2018

Database: Ovid MEDLINE(R) 1946 to Present with Daily Update

41 metasta* recurrence*.tw.
42 "Biochemical no Evidence of Disease".tw.
43 "Bio-chemical no Evidence of Disease".tw.
44 ((Biochemical* or bio-chemical*) adj1 recurrence*).tw.
45 Patient Discharge/ and exp Prostatic Neoplasms/
46 (Discharge* and prostat*).tw.
47 Self Care/ and exp Prostatic Neoplasms/
48 Self-Management/ and exp Prostatic Neoplasms/
49 ((self* adj1 (care* or manage*)) and prostat*).tw.
50 or/26-49
51 5 and 25 and 50
52 Animals/ not Humans/
53 51 not 52
54 Comment/ or Letter/ or Editorial/ or Historical article/ or (conference abstract or conference
paper or "conference review" or letter or editorial or case report).pt.
55 53 not 54
56 limit 55 to english language

Note: SIGN systematic review, RCT and observational study filters appended to strategy. Date limit applied from 2005 to 2018.

3 Study Design Filters

Table 13: study design filters

The MEDLINE systematic review, randomised controlled trials (RCT), diagnostic, and observational studies filters are presented below.

NICE Systematic review

1. Meta-Analysis.pt.
2. Network Meta-Analysis/
3. Meta-Analysis as Topic/
4. Review.pt.
5. exp Review Literature as Topic/
6. (metaanaly\$ or metanaly\$ or (meta adj3 analy\$)).tw.
7. (review\$ or overview\$).ti.
8. (systematic\$ adj5 (review\$ or overview\$)).tw.
9. ((quantitative\$ or qualitative\$) adj5 (review\$ or overview\$)).tw.
10. ((studies or trial\$) adj2 (review\$ or overview\$)).tw.
11. (integrat\$ adj3 (research or review\$ or literature)).tw.
12. (pool\$ adj2 (analy\$ or data)).tw.
13. (handsearch\$ or (hand adj3 search\$)).tw.
14. (manual\$ adj3 search\$).tw.
15. or/1-14
16. Animals/ not Humans/
17. 15 not 16

NICE RCT

1. Randomized Controlled Trial.pt.
2. Controlled Clinical Trial.pt.
3. Clinical Trial.pt.
4. exp Clinical Trials as Topic/
5. Placebos/
6. Random Allocation/
7. Double-Blind Method/
8. Single-Blind Method/
9. Cross-Over Studies/
10. ((random* or control* or clinical*) adj3 (trial* or stud*)).tw.
11. (random* adj3 allocat*).tw.
12. placebo*.tw.
13. ((singl* or doubl* or trebl* or tripl*) adj (blind* or mask*)).tw.
14. (crossover* or (cross adj over*)).tw.
15. or/1-14
16. Animals/ not Humans/
17. 15 not 16

SIGN Systematic review

1. Meta-Analysis as Topic/
2. meta analy\$.tw.
3. metaanaly\$.tw.
4. Meta-Analysis/
5. (systematic adj (review\$1 or overview\$1)).tw.
6. exp Review Literature as Topic/
7. or/1-6

The MEDLINE systematic review, randomised controlled trials (RCT), diagnostic, and observational studies filters are presented below.

8. cochrane.ab.
9. embase.ab.
10. (psychlit or psyclit).ab.
11. (psychinfo or psycinfo).ab.
12. (cinahl or cinhal).ab.
13. science citation index.ab.
14. bids.ab.
15. cancerlit.ab.
16. or/8-15
17. reference list\$.ab.
18. bibliograph\$.ab.
19. hand-search\$.ab.
20. relevant journals.ab.
21. manual search\$.ab.
22. or/17-21
23. selection criteria.ab.
24. data extraction.ab.
25. 23 or 24
26. Review/
27. 25 and 26
28. Comment/
29. Letter/
30. Editorial/
31. animal/
32. human/
33. 31 not (31 and 32)
34. or/28-30,33
35. 7 or 16 or 22 or 27
36. 35 not 34

SIGN RCT

- 1 Randomized Controlled Trials as Topic/
- 2 randomized controlled trial/
- 3 Random Allocation/
- 4 Double Blind Method/
- 5 Single Blind Method/
- 6 clinical trial/
- 7 clinical trial, phase i.pt
- 8 clinical trial, phase ii.pt
- 9 clinical trial, phase iii.pt
- 10 clinical trial, phase iv.pt
- 11 controlled clinical trial.pt
- 12 randomized controlled trial.pt
- 13 multicenter study.pt
- 14 clinical trial.pt
- 15 exp Clinical Trials as topic/
- 16 or/1-15
- 17 (clinical adj trial\$.tw
- 18 ((singl\$ or doubl\$ or treb\$ or tripl\$) adj (blind\$3 or mask\$3)).tw
- 19 PLACEBOS/

The MEDLINE systematic review, randomised controlled trials (RCT), diagnostic, and observational studies filters are presented below.

- 20 placebo\$.tw
- 21 randomly allocated.tw
- 22 (allocated adj2 random\$.tw
- 23 or/17-22
- 24 16 or 23
- 25 case report.tw
- 26 letter/
- 27 historical article/
- 28 or/25-27
- 29 24 not 28

McMaster Diagnosis studies

1. sensitiv:.mp. OR diagnos:.mp. OR di.fs.

Prostate Diagnosis subheadings (OVID)

1. Prostate/dg or Prostatic Neoplasms/dg

SIGN Observational studies

- 1 Epidemiologic studies/
- 2 Exp case control studies/
- 3 Exp cohort studies/
- 4 Case control.tw.
- 5 (cohort adj (study or studies)).tw.
- 6 Cohort analy\$.tw.
- 7 (Follow up adj (study or studies)).tw.
- 8 (observational adj (study or studies)).tw.
- 9 Longitudinal.tw.
- 10 Retrospective.tw.
- 11 Cross sectional.tw.
- 12 Cross-sectional studies/
- 13 or/1-12

Note: the following terms were removed from this filter for RQ9 searches:

- *exp case control studies/*
- *Case control.tw.*

4 Health economics search strategy

4.1 Economic evaluations and quality of life data

Sources searched to identify economic evaluations

- NHS Economic Evaluation Database – NHS EED (Wiley) last updated Dec 2014
- Health Technology Assessment Database – HTA (Wiley) last updated Oct 2016
- Embase (Ovid)
- MEDLINE (Ovid)
- MEDLINE In-Process (Ovid)
- Econlit (Ovid)

Search filters to retrieve economic evaluations and quality of life papers were appended to the population and intervention terms in the Ovid databases to identify relevant evidence between October 2017 and May 2018. Searches were then re-run in July 2018.

Table 14: Economic evaluation and quality of life filters

| Medline Strategy | |
|-----------------------------------|---|
| NICE Economic evaluations | |
| 1 | Economics/ |
| 2 | exp "Costs and Cost Analysis"/ |
| 3 | Economics, Dental/ |
| 4 | exp Economics, Hospital/ |
| 5 | exp Economics, Medical/ |
| 6 | Economics, Nursing/ |
| 7 | Economics, Pharmaceutical/ |
| 8 | Budgets/ |
| 9 | exp Models, Economic/ |
| 10 | Markov Chains/ |
| 11 | Monte Carlo Method/ |
| 12 | Decision Trees/ |
| 13 | econom*.tw. |
| 14 | cba.tw. |
| 15 | cea.tw. |
| 16 | cua.tw. |
| 17 | markov*.tw. |
| 18 | (monte adj carlo).tw. |
| 19 | (decision adj3 (tree* or analys*)).tw. |
| 20 | (cost or costs or costing* or costly or costed).tw. |
| 21 | (price* or pricing*).tw. |
| 22 | budget*.tw. |
| 23 | expenditure*.tw. |
| 24 | (value adj3 (money or monetary)).tw. |
| 25 | (pharmacoeconomic* or (pharmaco adj economic*)).tw. |
| 26 | or/1-25 |
| NICE Quality of life (QoL) | |
| 1 | "Quality of Life"/ |

Medline Strategy

- 2 quality of life.tw.
- 3 "Value of Life"/
- 4 Quality-Adjusted Life Years/
- 5 quality adjusted life.tw.
- 6 (qaly* or qald* or qale* or qtime*).tw.
- 7 disability adjusted life.tw.
- 8 daly*.tw.
- 9 Health Status Indicators/
- 10 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six or short form thirtysix or short form thirty six).tw.
- 11 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw.
- 12 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve).tw.
- 13 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short form sixteen).tw.
- 14 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form twenty).tw.
- 15 (euroqol or euro qol or eq5d or eq 5d).tw.
- 16 (qol or hql or hqol or hrqol).tw.
- 17 (hye or hyes).tw.
- 18 health* year* equivalent*.tw.
- 19 utilit*.tw.
- 20 (hui or hui1 or hui2 or hui3).tw.
- 21 disutili*.tw.
- 22 rosser.tw.
- 23 quality of wellbeing.tw.
- 24 quality of well-being.tw.
- 25 qwb.tw.
- 26 willingness to pay.tw.
- 27 standard gamble*.tw.
- 28 time trade off.tw.
- 29 time tradeoff.tw.
- 30 tto.tw.
- 31 or/1-30

SIGN Economic studies

- 1 Economics/
- 2 "costs and cost analysis"/
- 3 Cost allocation/
- 4 Cost-benefit analysis/
- 5 Cost control/
- 6 Cost savings/
- 7 Cost of illness/
- 8 Cost sharing/
- 9 "deductibles and coinsurance"/
- 10 Medical savings accounts/
- 11 Health care costs/
- 12 Direct service costs/
- 13 Drug costs/
- 14 Employer health costs/
- 15 Hospital costs/

Medline Strategy

- 16 Health expenditures/
- 17 Capital expenditures/
- 18 Value of life/
- 19 Exp economics, hospital/
- 20 Exp economics, medical/
- 21 Economics, nursing/
- 22 Economics, pharmaceutical/
- 23 Exp "fees and charges"/
- 24 Exp budgets/
- 25 (low adj cost).mp.
- 26 (high adj cost).mp.
- 27 (health?care adj cost\$).mp.
- 28 (fiscal or funding or financial or finance).tw.
- 29 (cost adj estimate\$).mp.
- 30 (cost adj variable).mp.
- 31 (unit adj cost\$).mp.
- 32 (economic\$ or pharmaco-economic\$ or price\$ or pricing).tw.
- 33 or/1-32

Note: The SIGN economics studies filter was appended to the strategies for RQ2 and RQ9 along with the NICE QoL filter.

The NICE economic evaluations and NICE QoL filters were appended to all other strategies.